Articles tagged with: Gilead Sciences

Grants awarded to 13 Canadian initiatives to help advance the goal of eliminating chronic Hepatitis C infection in high-risk populations

published: March, 22, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, Hep B and C, Current Affairs, Health, Revolving Door, Media, Guest Authors

Gilead Canada supports community leaders with local Hepatitis C micro-elimination efforts.

Grants awarded to 13 Canadian initiatives to help advance the goal of eliminating chronic Hepatitis C infection in high-risk populations

Mississauga, ON, March 14, 2018 – In support of Canada’s commitment to the World Health Organization’s (WHO) goal of eliminating chronic hepatitis C infection by 2030, Gilead Sciences Canada, Inc. (Gilead Canada) today announced a series of grants to support screening and linkage to care projects across Canada. These initiatives will focus on hepatitis C screening within high-risk patient populations and linking diagnosed patients to care. In total, 13 Hepatitis C Micro-Elimination Gran

HIV doesn’t define a parent’s power to love

published: March, 14, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, Gay Men, Mental Health, Research, International , Revolving Door, Living with HIV, Media, Guest Authors, Opinion Pieces

People living with HIV often feel cut off from society and judged by their decision to become parents. From FS Magazine, Mark Mesiti reports on an initiative to help end the stigma.

HIV doesn’t define a parent’s power to love

Photo © Shutterstock.com / WaveBreakMedia Despite significant medical advances, increased awareness and the ability to live a full life with HIV, a social stigma still exists around people with HIV having a family. This stigma does not just affect the LGBT community; it is very much a mainstream issue. Does a stigma exist? With almost 50% of HIV-positive respondents in a recent European study commissioned by Gilead Sciences stating that they felt having HIV would be a barrier to them ha

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys

published: March, 07, 2018 Written by // Guest Authors - Revolving Door Categories // Social Media, International AIDS Conference , As Prevention , Conferences, Current Affairs, Treatment Guidelines -including when to start, Research, Health, International , Revolving Door, Treatment, Media, Guest Authors

Five of eleven treated animals still remained virally suppressed at six months. From AIDSmap, Liz Highleyman reports.

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys

Dan Barouch presenting at CROI 2018. Photo by Liz Highleyman Treatment with a broadly neutralising antibody plus an immune-stimulating drug led to long-term viral remission after interrupting antiretroviral therapy in a monkey study, according to data presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) this week in Boston. Monkeys that received both the antibody, known as PGT121, and the TLR7 agonist GS-9620 maintained an undetectable viral load withou

Brazil fights HIV spike in youths with free preventive drug

published: December, 13, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, Youth, Current Affairs, Treatment Guidelines -including when to start, Women, Health, International , Revolving Door, Treatment, Media, Guest Authors

PrEP is being made available to prostitutes, transgender people, men who have sex with men, some drug users and people in relationships with partners who have H.I.V. From the New York Times, Shasta Darlington reports.

Brazil fights HIV spike in youths with free preventive drug

Piero Mori, right, and a friend both take PrEP, short for pre-exposure prophylaxis. “Condoms will always be the most complete protection,” Mr. Mori said. “But for those who just can’t or won’t use them, PrEP is a salvation. It protects you against the most serious disease.”  Credit: Dado Galdieri for The New York Times SÃO PAULO, Brazil — Seeking to stem a sharp rise in H.I.V. cases among young people, Brazil began offering a drug this month that can prevent infection to thos

People with HIV still expect a lower quality of life than their negative peers, European survey finds

published: October, 31, 2017 Written by // Guest Authors - Revolving Door Categories // Social Media, International AIDS Conference , As Prevention , Treatment Guidelines -including when to start, Mental Health, Health, International , Revolving Door, Treatment, Living with HIV, Media, Guest Authors

Nearly 40% with an undetectable viral load still consider themselves infectious. Gus Cairns reports on a European study commissioned by Gilead Sciences.

People with HIV still expect a lower quality of life than their negative peers, European survey finds

A study commissioned by the drug company Gilead Sciences and conducted in five European countries has found that, compared with their HIV-negative peers, people with HIV still expect to die sooner and think they are less likely to achieve a long-term relationship. The results were announced yesterday during the 16th European AIDS Conference (EACS 2017) in Milan, Italy. The survey found that 54% of HIV-positive people considered HIV to be a barrier to sex with others, and of them 87% (47% o

FDA approves a generic form of PrEP

published: June, 16, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, Youth, Current Affairs, Treatment Guidelines -including when to start, Women, International , Revolving Door, Treatment, Media, Guest Authors

Sexual health advocates hope this will make widen access to PrEP, the medication that helps prevent people contracting HIV

FDA approves a generic form of PrEP

To read the complete article by David Hudson visit Gay Star News, here. The Food and Drug Administration (FDA) in the US has approved the first generic form of PrEP. PrEP is medication that can be taken by someone to prevent them becoming infected with HIV. It’s a daily pill of Truvada, produced by Gilead Sciences. Truvada is a combination of Emtricitabine and Tenofovir Disoproxil Fumarate The use of PrEP has been credited with driving down HIV infection rates in countries where it has

The capsid inhibitor—a new class to enter clinical trials

published: April, 13, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // African, Caribbean and Black, Social Media, As Prevention , Gay Men, Youth, CATIE, Treatment Guidelines -including when to start, General Health, Women, Health, International , CATIE - HIV and Hep C Info Resource, Sexual Health, Treatment, Media

From CATIE: "This finding suggests that the capsid inhibitor has potential for intermittent dosing in people—perhaps every one or two months."

The capsid inhibitor—a new class to enter clinical trials

Most approved anti-HIV drugs work by interfering with an enzyme and/or protein that is needed by HIV-infected cells to make new viruses. A journey through the cell The capsid is the name given to the proteins that surround HIV’s genetic material. Upon HIV attaching itself to a target cell of the immune system, the virus sends its genetic material (RNA) into the cell. As the genetic material is surrounded by the capsid, it is protected from detection by the cell’s internal sensors. The ca

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017; new drugs, new hope and possible timelines

published: April, 07, 2017 Written by // CATIE - HIV and Hep C Info Resource Categories // Social Media, As Prevention , Gay Men, CATIE, Treatment Guidelines -including when to start, Research, CATIE - HIV and Hep C Info Resource, Treatment, Media

From CATIE, Sean R. Hosein reports on several new drugs that are in varying stages of development.

From the Conference on Retroviruses and Opportunistic Infections (CROI) 2017;  new drugs, new hope and possible timelines

Une version française est disponible ici. At the recent Conference on Retroviruses and Opportunistic Infections (CROI), which took place in Seattle from February 13 to 16, 2017, researchers presented data about new anti-HIV compounds in development, including the following: a new integrase inhibitor – bictegravir a new nuke (NRTI) – code-named GS-9131 a non-nuke (NNRTI) – doravirine a new protease inhibitor – code-named GS-PI1 a capsid inhibitor (a new cla

In the search for an HIV cure, David Evans explains “freedom” and how to better involve women & people of color

published: February, 21, 2017 Written by // Guest Authors - Revolving Door Categories // African, Caribbean and Black, Social Media, Women, Health, International , Revolving Door, Media, Guest Authors

From Betablog, Emily Newman reports on an ambitious HIV cure social science research project funded recently by Gilead Sciences.

In the search for an HIV cure, David Evans explains “freedom” and how to better involve women & people of color

To read the entire article by Emily Newman, visit Betablog, here. At an international AIDS Conference last year, David Evans, director of research advocacy at Project Inform, asked conference attendees to share their ideas about what an HIV cure—that worked for everyone and was freely available—would mean to them or the people they loved. “By far, the most common answer was ‘freedom,’” he said. “Whether it was freedom from stigma, from discrimination, or from knowing they would

Funders Concerned About AIDS (FCAA) report says philanthropic AIDS funding point highest since 2008

published: December, 29, 2016 Written by // Guest Authors - Revolving Door Categories // Social Media, Activism, Current Affairs, International , Revolving Door, Guest Authors

Global philanthropic funding up to $663 million but more resources, broader engagement needed to end epidemic

Funders Concerned About AIDS (FCAA) report says philanthropic AIDS funding point highest since 2008

Washington, D.C., December 5, 2016 – Funders Concerned About AIDS (FCAA), the leading voice on philanthropic resources for the global AIDS epidemic, today released its 14th annual Philanthropic Support to Address HIV/AIDS report. This year’s findings indicate that global philanthropic funding to fight the epidemic increased 10 percent from 2014, reaching $663 million, the highest level of funding since 2008. “Although the increase in philanthropic funding is encouraging, there is st

[12  >>